This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
by Zacks Equity Research
bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.
BIAFNegative Net Change
biotechnology biotechs earnings medical
First Western (MYFW) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MYFWNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Rivian Automotive (RIVN) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
RIVNNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Pagaya Technologies Ltd. (PGY) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PGYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
by Zacks Equity Research
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
REGNPositive Net Change BAYRYNegative Net Change HALONegative Net Change ALLOPositive Net Change
biotechnology biotechs dna-sequencing genomics medical pharmaceuticals
Company News for May 20, 2025
by Zacks Equity Research
Companies In The News Are: NVAX, REGN, RYAAY, ZIM.
RYAAYNegative Net Change REGNPositive Net Change NVAXNegative Net Change ZIMNegative Net Change
biotechnology transportation
Stock Market News for May 20, 2025
by Zacks Equity Research
U.S. stock markets closed higher on Monday after a choppy session.
GILDNegative Net Change
biotechnology
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
by Ekta Bagri
At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.
BMYNegative Net Change AMGNPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
by Zacks Equity Research
NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Best Momentum Stocks to Buy for May 19th
by Zacks Equity Research
CADL, HMN and MAG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 19, 2025.
HMNNegative Net Change MAGNegative Net Change CADLNegative Net Change
biotechnology
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
by Zacks Equity Research
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
BAYRYNegative Net Change HALONegative Net Change ACADNegative Net Change NTLAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Compass Minerals (CMP) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CMPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Northrim BanCorp (NRIM) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NRIMNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Calix (CALX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CALXNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Home Bancorp (HBCP) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
HBCPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
by Ahan Chakraborty
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Insteel Industries (IIIN) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
IIINNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock
by Ahan Chakraborty
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
After Golden Cross, Allient (ALNT)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ALNTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Amphenol (APH) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
APHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Air Lease (AL) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ALNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
by Zacks Equity Research
Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.
BAYRYNegative Net Change EXELNegative Net Change EDITNegative Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales
by Zacks Equity Research
BAYRY's first-quarter earnings beat expectations. Revenues miss estimates, mainly due to lower sales of its products in the Crop Science division.
REGNPositive Net Change AZNPositive Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
After Golden Cross, Telefonica Brasil (VIV)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
VIVPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.
AZNPositive Net Change BAYRYNegative Net Change EDITNegative Net Change ALLOPositive Net Change
biotechnology biotechs crispr earnings medical pharmaceuticals